Tech Company Financing Transactions
Antiva Biosciences Funding Round
Antiva Biosciences closed a $53 million Series E financing round on 4/27/2023. Backers included Adjuvant Capital, BioImpact Capital and Canaan Partners.
Transaction Overview
Company Name
Announced On
4/27/2023
Transaction Type
Venture Equity
Amount
$53,000,000
Round
Series E
Investors
Canaan Partners (Wende Hutton)
Sofinnova Ventures (David Kabakoff)
Proceeds Purpose
The company intends to use the funds for the advancement of its lead development candidate, ABI-2280, into key efficacy studies following completion of its ongoing Phase 1 trials.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
14024 Rue Saint Raphael
Del Mar, CA 92014
USA
Del Mar, CA 92014
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
Antiva Biosciences was founded by Karl Hostetler, M.D., a leader in virology who founded Chimerix, Triangle Therapeutics (acquired by Gilead) and Vical. The company is using a new medicinal chemistry platform to develop antiviral therapies, focusing first on HPV. Antiva has additional molecules that target HIV, the herpes virus, cytomegalovirus and others.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Founder
Karl Hostetler
Browse more venture capital transactions:
Prev: 4/27/2023: Energy Dome venture capital transaction
Next: 4/27/2023: Foresight Diagnostics venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs